m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells

Liang, Hao; Wang, Jiamei; Liu, Bao-Qin; Yan, Jun; Li, Chao; Jiang, Jingyi; Zhao, Fu-Ying; Qiao, Huaiyu; Wang, Hua‐Qin

doi:10.1016/j.bbamcr.2020.118878

Cited by 91 publications

(76 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The abnormal expression of lncRNAs could promote the proliferation, migration, invasion, and metastasis of OC by regulating the mRNAs expression and contribute to poor prognosis of OC (20). It has been confirmed that the AC006262.3 related genes such as VASP (21), RUNX1 (22), TRIM29 (23) in Figure 2C contribute to the progression of OC. Thus, the aberrant expression of lncRNAs may serve as new prognostic biomarkers in OC.…”

Section: Discussionmentioning

confidence: 86%

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer

Wang

Yao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

AimsDysregulated long noncoding RNAs (lncRNAs) contributing to ovarian cancer (OC) development may serve as prognostic biomarker. We aimed to explore a lncRNA signature to serve as prognostic biomarker of OC.MethodsUnivariate Cox regression was conducted on the lncRNA expression dataset from the TCGA cohort, and 246 genes significantly associated with survival were retained for building a model. A random forest survival model was carried out, and a model was developed using 6 genes with the highest frequency. The selected genes were applied in a Cox multivariate regression model for prognostic prediction by calculating the risk score. We also used CCK-8, EdU, and colony formation assays to validate the function of these lncRNAs in OC cells.ResultsThis study confirmed that the 6-lncRNA combined signature was related to OC prognosis. Systematic analysis demonstrated that lncRNA-associated genes were enriched in oncogenic signalling pathways. Five out of the 6 lncRNAs participated in OC proliferation.ConclusionWe established a 6-lncRNA combined signature for OC prognosis, which may serve as powerful prognostic biomarker for OC after further validation.

show abstract

Section: Discussionmentioning

confidence: 86%

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer

Wang

Yao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition, cancer stem cells (CSCs) are a population of cells with stem-like characteristics that are able to cause chemoresistance and recurrence. YTHDF1 was found to enhance the CSC-like characteristics of the cisplatin-resistant ovarian cancer cells by binding to m6A-modified TRIM29 mRNA and promoting its translation (64). Thus, targeting YTHDF1 is expected to be a promising candidate for ovarian cancer therapy.…”

Section: Ovarian Cancermentioning

confidence: 99%

“…Up-regulation of YTHDF1 is associated with the poor prognosis of ovarian cancer patients and knockdown of YTHDF1 can inhibit the stem cell-like features of cisplatin-resistant ovarian cancer cells. YTHDF1 may have strong potential as a therapeutic target for ovarian cancer (63,64).…”

Section: Potential Application Of Yth Family Proteins In Cancer Therapymentioning

confidence: 99%

Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers

Dai

Shi

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Among the over 150 RNA modifications, N6-methyladenosine (m6A) is the most abundant internal modification in eukaryotic RNAs, not only in messenger RNAs, but also in microRNAs and long non-coding RNAs. It is a dynamic and reversible process in mammalian cells, which is installed by “writers,” consisting of METTL3, METTL14, WTAP, RBM15/15B, and KIAA1429 and removed by “erasers,” including FTO and ALKBH5. Moreover, m6A modification is recognized by “readers,” which play the key role in executing m6A functions. IYT521-B homology (YTH) family proteins are the first identified m6A reader proteins. They were reported to participate in cancer tumorigenesis and development through regulating the metabolism of targeted RNAs, including RNA splicing, RNA export, translation, and degradation. There are many reviews about function of m6A and its role in various diseases. However, reviews only focusing on m6A readers, especially YTH family proteins are few. In this review, we systematically summarize the recent advances in structure and biological function of YTH family proteins, and their roles in human cancer and potential application in cancer therapy.

show abstract

“…In recent years, many studies have revealed that m 6 A plays an important role in the formation of many kinds of tumors, such as breast cancer [41,42], ovarian cancer [43,44], cervical cancer [45], acute myeloid leukemia [46][47][48], glioblastomas [49][50][51], non-small cell lung cancer [52][53][54][55], hepatocellular cancer [56][57][58][59], gastric cancer [60], colorectal cancer [61], pancreatic cancer [62], etc. Furthermore, it is found that m 6 A modification plays a key role in tumor radiotherapy, chemotherapy and drug therapy.…”

Section: Hnrnpcmentioning

confidence: 99%

Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

In recent years, with the development of RNA sequencing technology and bioinformatics methods, the epigenetic modification of RNA based on N6-methyladenosine (m6A) has gradually become a research hotspot in the field of bioscience. m6A is the most abundant internal modification in eukaryotic messenger RNAs (mRNAs). m6A methylation modification can dynamically and reversibly regulate RNA transport, localization, translation and degradation through the interaction of methyltransferase, demethylase and reading protein. m6A methylation can regulate the expression of proto-oncogenes and tumor suppressor genes at the epigenetic modification level to affect tumor occurrence and metastasis. The morbidity and mortality of esophageal cancer (EC) are still high worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common tissue subtype of EC. This article reviews the related concepts, biological functions and recent advances of m6A methylation in ESCC, and looks forward to the prospect of m6A methylation as a new diagnostic biomarker and potential therapeutic target for ESCC.

show abstract

m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells

Cited by 91 publications

References 37 publications

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer

A Combined Long Noncoding RNA Signature as a Candidate Prognostic Biomarker for Ovarian Cancer

Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers

Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About